BA
TARA icon

Ballew Advisors’s Protara Therapeutics TARA Stock Holding History

Ballew Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed – – 396
2018
Q3 		$0 Buy
+1
New +$92 ﹤0.01% 515

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Ballew Advisors's TARA Position: Q4 2018 in Review

Ballew Advisors sold out of Protara Therapeutics (TARA) in Q4 2018, closing a stake of 1 share.

Ballew Advisors first reported a position in TARA in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 27 funds tracked by Wall St. Rank hold TARA as of Q4 2018.

  • Ballew Advisors reported no remaining Protara Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ballew Advisors sold 1 Protara Therapeutics share in Q4 2018.
  • Ballew Advisors first reported a position in Protara Therapeutics in Q3 2018 and held it in 1 quarter.
  • Ballew Advisors's Protara Therapeutics position peaked at $0 in Q3 2018.
  • 27 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.